Edoxaban or Vitamin K Antagonist for Atrial Fibrillation after TAVR. Reply

Nicolas van Mieghem, Martin Unverdorben, George D. Dangas

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

26 Downloads (Pure)

Original language	English
Pages (from-to)	804
Number of pages	1
Journal	New England Journal of Medicine
Volume	386
Issue number	8
DOIs	https://doi.org/10.1056/NEJMc2120127
Publication status	Published - 24 Feb 2022

Access to Document

@article{f2c7fcb4393344f1827ce22e84d3eaaf,

title = "Edoxaban or Vitamin K Antagonist for Atrial Fibrillation after TAVR. Reply",

author = "{van Mieghem}, Nicolas and Martin Unverdorben and Dangas, {George D.}",

year = "2022",

month = feb,

day = "24",

doi = "10.1056/NEJMc2120127",

language = "English",

volume = "386",

pages = "804",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "8",

}

TY - JOUR

T1 - Edoxaban or Vitamin K Antagonist for Atrial Fibrillation after TAVR. Reply

AU - van Mieghem, Nicolas

AU - Unverdorben, Martin

AU - Dangas, George D.

PY - 2022/2/24

Y1 - 2022/2/24

UR - http://www.scopus.com/inward/record.url?scp=85125213369&partnerID=8YFLogxK

U2 - 10.1056/NEJMc2120127

DO - 10.1056/NEJMc2120127

M3 - Comment/Letter to the editor

SN - 0028-4793

VL - 386

SP - 804

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 8

ER -